



ASX ANNOUNCEMENT

Starpharma presenting at Nomura Asian equity forum

Melbourne Australia; 11 June 2013 - Starpharma Holdings Ltd (ASX: SPL; OTCQX: SPHRY) will participate in the Nomura Asia Equity Forum in Singapore.

The forum, held June 10 – 12, has attracted more than 1,500 delegates including management from 133 companies and more than 1,000 investors. Starpharma is one of two Australian-based biotech companies to present at the forum, the other being Mesoblast.

"Starpharma welcomes this opportunity to present the company to a wider set of investors from across Asia and to build on an already strong and international institutional base," said CEO Dr Jackie Fairley.

The presentation will provide an overview of Starpharma's business and portfolio including:

- Starpharma's lead product, VivaGel® for the management of bacterial vaginosis including the first-in-class prevention of recurrence product and opportunity for symptomatic relief;
- The VivaGel® coated condom product currently under regulatory review and licensed to Ansell and Okamoto;
- Drug delivery, including Starpharma's dendrimer-docetaxel nanoparticle formulation; and
- its agrochemical program, including the recent partnership with Makhteshim Agan.

The presentation is attached.

ABOUT STARPHARMA

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical uses. Starpharma has three core development programs: VivaGel® portfolio, drug delivery, and agrochemicals with the Company developing a number of products internally and others via commercial partnerships.

Starpharma's lead product is VivaGel® (SPL7013 Gel), a gel-based formulation of a proprietary dendrimer. VivaGel® is under clinical development for the treatment and prevention of bacterial vaginosis (BV) and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes. Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto Industries Inc (Tokyo Stock Exchange) to market a value-added, VivaGel®-coated condom. Ansell manufactures and sells leading condom brands worldwide, including

Lifestyles®, ZERO® and SKYN®. Okamoto is the market leader for condoms sold in Japan, the world's second largest condom market.

In the wider pharmaceutical and life science fields, Starpharma has both partnered and internal programs in Drug Delivery. Drug Delivery partners include GSK, Lilly and AstraZeneca. In its internal program Starpharma has announced significant tumour-targeting results in its docetaxel (Taxotere®) program, with animal studies showing its dendrimer-enhanced version of docetaxel to have significantly superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel).

In agrochemicals Starpharma has a series of partnerships with leading industry players including Nufarm (ASX:NUF) and Makhteshim Agan as well as internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®).

FOR FURTHER INFORMATION

Media:**Buchan Consulting**

Rebecca Wilson

Mob: +61 417 382 391

rwilson@buchenwe.com.au

Danny Rose

Mob: +61 407 25 00 88

drose@buchenwe.com.au**Starpharma:**Dr Jackie Fairley, Chief Executive Officer
+61 3 8532 2704

Ben Rogers, Company Secretary

ben.rogers@starpharma.comwww.starpharma.com**Forward Looking Statements**

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.



starpharma



STARPHARMA HOLDINGS LIMITED

ASX:SPL; OTCQX:SPHRY

Nomura Asia Equity Forum

11 &12 June 2013
Dr. Jackie Fairley CEO





This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.



A global leader in nanoscale polymers called Dendrimers:
Versatile technology & portfolio of commercial assets



VivaGel® Portfolio:

- VivaGel® for Bacterial Vaginosis (BV): Late stage Clinical Asset
- Two attractive commercial licences for VivaGel®-coated condom: Ansell (#2 globally) and Okamoto (Japanese market leader)
- VivaGel® Microbicide Gel for HIV/HSV2/HPV prevention (STIs); Phase 2

Dendrimer Drug Delivery technology:

- Dendrimer-docetaxel nanoparticle demonstrated significant advantages vs. Taxotere®
- Multiple Pharma. partnerships - half Top 10 Companies (incl. Lilly, AstraZeneca, GSK, multiple undisclosed)

Dendrimers in Agrochemicals:

- Internal candidates in generic Agrochemicals incl. glyphosate (Roundup®)
- Multiple Agrochemical partnerships incl. Nufarm (ASX:NUF), Makhteshim Agan.



Corporate and financial information


- Market cap: ~ A\$230 million
- Shares on issue: ~284 million
- Strong institutional register
 - 29% International Inst.
 - 28% Australian Inst.
- Major shareholders
 - Acorn, M&G, Allan Gray, Dow Chemical

Key Financial Data	FY 2012^ AUD \$M
Total revenue and income	2.9
Net loss after tax	13.7
Cash outflow from operations	(9.8)
^ Cash (as at 31/3/13)	\$35.9

Analyst Ratings			Target Price	*Price Upside
 CIMB	4-Apr-13	Buy (Outperform)	\$1.79	98%
 NOMURA	3-Apr-13	Buy	\$1.69	90%
 CANACCORD GENUITY	5-Apr-13	Buy	\$2.00	125%
 BELL POTTER	4-Apr-13	Buy	\$1.58	78%
 PhillipCapital	4-Apr-13	Buy	\$1.90	113%
 TAYLOR COLLISON	4-Apr-13	Hold	\$1.15	29%
<i>* Price upside based on closing at \$0.89 15/5/13</i>			Av. Target Price \$1.69	Av. Upside 89%




Significant Optionality: Potential for multiple and parallel revenue streams





Leverage platform: multiple products with parallel revenue streams

Product/ Application	Commercial Strategy / Partnering Status	Potential Market USD	SPL Returns
VivaGel® Bacterial Vaginosis	License at late stage	<ul style="list-style-type: none"> Prevention Recurrence >\$1B Treatment/Symptomatic: ~ \$350M 	Royalty/milestones
VivaGel® Coated Condom	Partnered with Ansell and Okamoto	Branded Condom Market: \$1.1B	Royalties
VivaGel® Ophthalmic	Currently Internal: early partnering	Viral Conjunctivitis Market ~ \$700M	Co-development/ Royalty/milestones
Drug Delivery	<ul style="list-style-type: none"> Multiple Partnered (Lilly, GSK, AZ, undisclosed) Internal: Docetaxel 	<ul style="list-style-type: none"> Multiple Partner Funded Multi billion docetaxel sales 	Royalty/milestones Royalty/milestones
Agrochemicals	<ul style="list-style-type: none"> Multiple Partnered; Nufarm, MA & undisclosed Internal: glyphosate, solvent removal, others 	<ul style="list-style-type: none"> Multiple Partner Funded (royalties/downstream returns) 2. Internal : ~\$5 B (glyphosate), others. 	Royalties Royalties



VivaGel®- coated condom

- Condom coated with patented antiviral dendrimer - VivaGel® Kills ≥ 99.99% HIV & Herpes
- Licensed to Ansell and Okamoto
 - Consumer research, product positioning, package design, manufacturing validation undertaken
- Combination product /Device Route: Regulatory reviews underway
- Branded condom market: \$1.1B
- VivaGel® Patents to 2027

Partner	Market Position/Share	Major Brands
<u>Okamoto Industries</u> (listed on TSE) 	<ul style="list-style-type: none"> • No. 1 in Japan with ~60% Japanese market (the 2nd largest condom mkt. Est. ~U\$500M) • Total company revenues >USD 760M 	Skinless®  003® 
<u>Ansell Limited</u> ASX:ANN 	<ul style="list-style-type: none"> • No. 2 globally for condom sales ~ 20% global share of branded market ~\$1.1B • Condom business growing ~18% 	Lifestyles® SKYN® ZERO® Manix® 



Bacterial Vaginosis(BV): Attractive Commercial Opportunity and Unmet Need



- Bacterial Vaginosis (BV): the most common vaginal infection worldwide
- ~29% women infected in US[^]; up to 51% in certain demographics
- Caused by overgrowth of pathogenic bacteria* & *reduction of normal flora (lactobacilli spp.)*
- BV causes unpleasant discharge, irritation; PID/infertility, preterm birth, increased risk STIs e.g. HIV
- Recurrent BV an issue in 50-60% of BV sufferers

BUT current antibiotic treatments have significant shortcomings:

- Low cure rates; High rates of recurrence and antibiotic resistance
- Adverse features common: GI toxicity, 2^o candida, incompatibility with alcohol and condoms
- Not suitable for long term use
- Current global market for BV treatments : approx. US\$300-350M; also OTC vaginosis markets
- No products approved to prevent BV Recurrence (market est. >\$1B)




VivaGel® in Bacterial Vaginosis: Two product opportunities

Indication	Current Market/est.	Existing therapies	Stage of Development	Commercial Strategy
Prevention of BV Recurrence	Est. > US\$1B	None approved	<ul style="list-style-type: none"> - Phase 2 Trial results reported April 2013; - Phase 3 Planning underway 	Late stage License
Bacterial Vaginosis Treatment/ Symptomatic Relief	~US \$300M	Metronidazole Clindamycin (antibiotics) and various OTC	<ul style="list-style-type: none"> - Phase 3 Completed Efficacy at 5-7 days but not at FDA endpoint; - Symptomatic claims being pursued 	Late stage License

Benefits of VivaGel®:

- Designed for Chronic use
- Not systemically absorbed
- Lack toxicities associated with antibiotics
- Selective antimicrobial effect





Prevention of recurrence of BV: Phase 2 Trial Results Summary

- Double-blind exploratory Phase 2 trial in 205 US women (VivaGel® vs. placebo)
- 1% VivaGel® demonstrated reduced risk of recurrent BV (by all measures) and delayed time to first recurrence (35d vs. 5d)
- More than 80% of 1% VivaGel® users remained BV free at 16 weeks; excellent symptomatic relief
- High levels of patient satisfaction (79% satisfied/extremely satisfied); VivaGel® was safe and well tolerated
- Results strongly support progression to Phase 3 following regulatory input

R-BV Def.	R-BV Criteria	Treatment		Relative Risk Reduction (1% VivaGel vs. Placebo)
		1% SPL7013 Gel (N=65)	Placebo Gel (N=61)	
1	FDA stipulated Amsel	12%	28%	56%
2	Patient symptoms & Amsel	17%	28%	39%
3	At least 3 of the 4 Amsel criteria	22%	34%	38%
4	Investigator's determination	20%	31%	36%


*"as a clinician I am very encouraged by the data for 1% VivaGel®.
In this group of women almost all would have been expected to experience recurrent BV during the study. However 80% of VivaGel users remained BV free at 16 weeks.*

I see this finding as highly promising – both for the management of women with this condition and for recurrent BV sufferers."

Prof. George Kinghorn, Dept. GU Medicine,
Royal Hallamshire and Sheffield, UK




Phase 2 BV Prevention of Recurrence Results – Trial Design





Phase 2 BV Prevention of Recurrence Results: VivaGel® demonstrates excellent symptomatic relief

Patient reported symptoms: Symptomatic relief




* Statistically significant ($P \leq 0.05$) vs. placebo



VivaGel®: Partnering and Market Opportunity for Recurrent BV

- Potential partners see Prevention of Recurrence as a “game changing” indication > \$1B
- Active engagement with ~10 top tier companies in women’s health
- Partnering discussions continuing in parallel with planning for Phase 3 trials



Prevention
of
Recurrence
indication:

- No approved products
- Off label use of existing products have considerable shortcomings
- High unmet need from physicians and patients with significant population of affected women
- VivaGel® demonstrated to be very safe in clinical studies >500 women
- VivaGel® is applied topically and not systemically absorbed therefore considered a better option for long term therapy



VivaGel®: Phase 3 Trial - Treatment and Symptomatic relief of BV

Key Findings:

- VivaGel® demonstrates statistically significant Clinical Cure and effectiveness in treating symptoms of BV at the end of treatment (EOT)
- Primary FDA endpoint for Treatment (Cure at 2-3 weeks after cessation of treatment) not met
- Excellent safety profile including very low rates of candidiasis (cf. other products)
- Patient acceptability very positive
- VivaGel® treated women reporting rapid and sustained relief from symptoms


Given the efficacy shown for VivaGel® at end of treatment and excellent symptom data:

- other claim strategies such as symptomatic relief being explored with both regulators and partners plus and other regulatory jurisdictions
- Confounding factors including unusually high efficacy in placebo at some trial sites being discussed with FDA/Regulators




Phase 3 BV Treatment Trial

- Two Phase 3 double-blind, placebo controlled studies
- Conducted in US/EU under IND (SPA) to achieve BV Treatment Claim
- ~250 patients per trial





Phase 3 Treatment – Symptomatic Relief




The next day I noticed a huge difference....."
– Patient

"I would definitely use it again. ... it's very effective." – Patient


It was like gone almost overnight." – Patient

the symptoms went away much quicker than the first one that I had." --Patient





Dendrimers in Drug Delivery: Nanoparticles with multiple advantages




Feature	Potential Benefits for Patients and/or Manufacturers
Improved Drug Efficacy	More effective treatments or lower doses
Reduced Toxicity of Actives	Reduced side-effects
Improved Drug Solubilisation	Less toxic formulations (allowing removal of toxic excipients) Less painful injection formulations
Improved Pharmacokinetics	Less frequent dosing and less severe side effects
Targeted Drug Delivery	More effective treatments; reduced side effects
Product lifecycle management	Extension of patent life: Proprietary nanoparticle formulation



Dendrimer-docetaxel Nanoparticle Formulation: Multiple Benefits

- Taxotere® (docetaxel) is a blockbuster chemotherapeutic; 2011 sales of US\$1.2B
- Docetaxel is used in major cancer types including breast, prostate and lung cancer
- Starpharma's patented Dendrimer-Docetaxel Nanoparticle formulation has several significant advantages compared to original formulation of docetaxel (Taxotere®)
- Patents filed will offer coverage 2032
- Planning underway to enter clinical trials 2013



Dendrimer-Docetaxel vs. Taxotere®

1. Improved water solubility allowing removal of toxic components
2. Tumour-targeting (preferential delivery to cancer tissue)
3. Extended half-life
4. Improved efficacy (breast cancer model)



Dendrimer- Docetaxel Benefits: Efficacy and Toxicity

- Docetaxel is insoluble so Taxotere® incorporates a detergent to solubilize it, which is associated with significant toxicity
 - Dendrimer–Docetaxel Nanoparticle formulation is water soluble and has significantly^ better efficacy than Taxotere®
 - Efficacy: At 94 days:
 - 60% dendrimer-docetaxel mice - no evidence of tumour
 - 100% Taxotere® mice - tumour re-growth


Starpharma's detergent-free Dendrimer-docetaxel
(solubility \uparrow 2000-8000x)

Efficacy: Breast Cancer Model*



PBS 19d Dendrimer-Docetaxel 19d

Mean Tumour Volume (MDA-MB-231)



Animals Dosed on days 1, 8 and 15


*Mouse Xenograft (MDA- MB 231); N= 10/group ;

^a p<0.0001



Dendrimer-docetaxel benefits: Tumour Targeting and Half Life

- Dendrimer–Docetaxel Nanoparticle formulation extends plasma half life by at least 60 fold vs. Taxotere® enabling sustained delivery of docetaxel
- Dendrimer–Docetaxel formulation provides > 40 fold greater docetaxel accumulation in the tumour tissue compared to Taxotere® 3 days after administration



	Plasma Half Life (hours) ^
Dendrimer – Docetaxel Nanoparticle	39
Docetaxel (Taxotere)	0.5

[^]n = 4 rats per group



Broad potential for dendrimer nanoparticles to improve major drugs

- Starpharma's dendrimer nanoparticle technology has broad applicability
- Analysis shows dendrimers applicable to >50% of leading pharmaceuticals
- Significant potential in oncology
- Proof of concept in docetaxel, doxorubicin, paclitaxel, platinums

Also Suited to:

- Proteins (ie. Insulin), peptides
- Antibody Drug Conjugates or ADCs : Chemotherapeutic + antibody

Nanomedicine-based oncology drug sales expected to grow to \$12.7B by 2016 (CAGR 18%)


*Nanotechnology in Medical Applications:
The Global Market
BCC 2012*

Brand	Molecule	Innovator Company	2009 Sales (\$ M USD)
Taxotere	Docetaxel	Sanofi Aventis	2,140
Eloxatin	Oxaliplatin	Sanofi Aventis	1,484
Alimta	Pemetrexed	Eli Lilly	1,306
Gemzar	Gemcitabine	Eli Lilly	1,107
Doxil/ caelyx	Pegylated doxorubicin	JnJ / Merck	384
Camptosar	Irinotecan	Pfizer	329
Abraxane	Albumin bound paclitaxel	Celgene	310
Vidaza	Azacitidine	Celgene	299
Taxol	Paclitaxel	BMS	292
Treanda	Bendamustine	Cephalon/ Astellas	241

**Deals in Nanomedicine
\$700M in 2013
Amgen, Pfizer, AZ
(preclinical candidates)**




Dendrimers for Drug Delivery - Proteins and Peptide Drugs



Approach	Conjugate protein or peptide to functionalised dendrimer
Benefit	<p>Control half life of protein or peptide therapeutics</p> <p>Improve dosing regimen</p> <p>Reduce protein metabolism</p>
Status	<p><i>in vivo</i> using insulin for proof of concept achieved</p> <p>Co-development program with undisclosed partner</p>

In vivo mouse model



Dendrimer insulin shows prolonged suppression of blood glucose *in vivo*



Dendrimers in Agrochemicals

Dendrimers can enhance the performance of existing agrochemicals and create proprietary (patentable) formulations through:

- Extension/enhancement of effect
- Solubility enhancement
- Reduction/removal solvents – “greener” formulations
- Modification of soil penetration
- Protection of Actives/Sequestration

Partnerships with >50% leading global Ag. Companies



Reduced Hydrocarbon Formulations

- **Solvent-based pesticides** make up ~**US\$10BN** of the global US\$40BN agrochemical market
- Dendrimers can increase water solubility of these active ingredients **reducing the need for hydrocarbons**
- Starpharma's aim is to develop formulations which offer:
 - **Improved environmental profile** due to a reduction in those hydrocarbon solvents that are considered harmful, including xylene, naphthalene and benzene.
 - **Improved user and operator safety** due to the lowered solvent loading
 - Lower transport costs and improved safety due to **reduced flammability**



Agrochemicals: Dendrimer glyphosate formulation

- Starpharma's initial results:
 - Glyphosate (e.g. Roundup®) effectiveness measured using "brownout" (rate of vegetation dying off)
 - Starpharma's dendrimers improved performance of glyphosate by ~160-320% compared to glyphosate alone
- Glyphosate market is US\$5B globally
- Additional work also undertaken on key generic actives

including:

- Imidacloprid (e.g. Confidor®) globally US\$1B
- Trifluralin (e.g. Treflan™) globally US\$300M





Photo depicting "brownout"




Agrochemicals: Multiple Applications in Leading Products


Enhanced Efficacy




Improved Soil Penetration



Improved Rain-fastness



Improved Loading





Agrochemicals: Significant Potential to improve off-patent actives

*Significant opportunity, for both
proprietary & generic actives*

>\$5B ...the value of
products
coming off patent
2011-16
Phillips McDougall.
2010 Sales Value, US\$

Herbicides	\$2,237M
Insecticides	\$1,858M
Fungicides	\$1,151M

Active Ingredient	Activity	Market Value (\$M USD)
Glyphosate	Herbicide	5000
Imidacloprid	Insecticide	1000
Acephate	Insecticide	350
Pendimethalin	Herbicide	350
Acetochlor	Herbicide	300
Chlorpyrifos	Insecticide	300
Trifluralin	Herbicide	300



Leverage platform: multiple products with parallel revenue streams

Product/ Application	Commercial Strategy / Partnering Status	Potential Market USD	SPL Returns
VivaGel® Bacterial Vaginosis	License at late stage	<ul style="list-style-type: none"> Prevention Recurrence >\$1B Treatment/Symptomatic: ~ \$350M 	Royalty/milestones
VivaGel® Coated Condom	Partnered with Ansell and Okamoto	Branded Condom Market: \$1.1B	Royalties
VivaGel® Ophthalmic	Currently Internal: early partnering	Viral Conjunctivitis Market ~ \$700M	Co-development/ Royalty/milestones
Drug Delivery	<ul style="list-style-type: none"> Multiple Partnered (Lilly, GSK, AZ, undisclosed) Internal: Docetaxel 	<ul style="list-style-type: none"> Multiple Partner Funded Multi billion docetaxel sales 	Royalty/milestones Royalty/milestones
Agrochemicals	<ul style="list-style-type: none"> Multiple Partnered; Nufarm, MA & undisclosed Internal: glyphosate, solvent removal, others 	<ul style="list-style-type: none"> Multiple Partner Funded (royalties/downstream returns) 2. Internal : ~\$5 B (glyphosate), others. 	Royalties Royalties



Investment Summary

Strategy: commercially exploit dendrimer platform to generate multiple, parallel revenue streams

- A highly versatile, proprietary technology platform
- Deep and diversified portfolio
- Near term commercial and clinical milestones
- An impressive and growing portfolio of commercial partnerships
- Multiple, well advanced potential revenue streams





A platform technology with broad optionality and applicability

VivaGel®


Lead internal program:

VivaGel for the treatment and prevention of Bacterial Vaginosis.

Partnered development programs:

Ansell

okamoto



Agrochemical

Drug Delivery

Lead internal program:
dendrimer-docetaxel
(Taxotere)

Partnered development programs:



Lead internal program:
dendrimer-glyphosate
(Roundup®)

Partnered development programs:

